))
Journal Club: Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
Manage episode 462594593 series 3626024
Contenido proporcionado por IGCS Education360 Podcast. Todo el contenido del podcast, incluidos episodios, gráficos y descripciones de podcast, lo carga y proporciona directamente IGCS Education360 Podcast o su socio de plataforma de podcast. Si cree que alguien está utilizando su trabajo protegido por derechos de autor sin su permiso, puede seguir el proceso descrito aquí https://es.player.fm/legal.
Listen to a new Journal Club with PI Dr. Brian Slomovitz and moderator Dr. Leslie Randall as they discuss details on the New England Journal of Medicine published article Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer.
Click here to read the article
Presented by
Brian Slomovitz
Director of Gynecologic Oncology
Co-Chair, Cancer Research Committee
Mount Sinani Medical Center
USA
Moderated by
Leslie Randall
Director of Gynecologic Oncology Clinical Research and Gynecologic Cancer Service Line
Inova Schar Cancer Institute
Inova Health System
USA
Supported in part by Pfizer | Genmab
6 episodios
Compartir
